Jan Van Heek

Mr. van Heek is currently a board member of Amarin Corporation, and Minerva Neurosciences, both publicly traded biopharmaceutical companies. Since 2009, Mr. van Heek has been a Principal and Partner at BioPoint Group, a business development consulting company. Prior to establishing BioPoint in 2009, Mr. van Heek spent more than 18 years at Genzyme Corporation, a Sanofi pharmaceutical company, most recently as Executive Vice President and Senior Advisor to the chief executive officer and senior management team. He was also a board member and Chairman of the Audit Committee of ViaCell Corporation, a public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an MBA from St. Gallen University in Switzerland and an executive degree from Stanford Business School.